Letting the tumour decide who needs chemo
For a lot of women with early breast cancer, chemotherapy has been the default answer to a hard question nobody could answer precisely: will this cancer come back? If a tumour looked risky, was large, or had reached the lymph nodes, the safe move was to give chemo and accept the cost, the sickness, the hair loss, the fatigue that can drag on for months, and the small but real long-term risks. The problem is that many of those people were never going to relapse anyway. They took the poison for nothing.
The OPTIMA trial set out to sort the two groups apart, and its first results say a simple gene test can do it. Across 4,429 patients in six countries, doctors let a 50-gene tumour test decide who actually needed chemotherapy. Two thirds of these high-risk patients, 68%, were told they could skip it. Five years on, they have done almost exactly as well as the patients who got standard chemotherapy.
That is the rare kind of trial result that takes something away, the chemo, and loses nothing measurable in return.
| Finding | Plain-English meaning |
|---|---|
| 68% of high-risk patients could skip chemotherapy | Two in three people whose doctors had recommended chemo had tumours the gene test scored as low risk. |
| 90.3% vs 91.8% free of invasive cancer at 5 years | The test-guided group did almost as well as the standard-chemo group; the 1.5-point gap met the trial’s bar for “no meaningful difference.” |
| 4,429 patients across 6 countries | A large international trial (UK, Norway, Sweden, Australia, New Zealand, Thailand), not a single-centre study. |
| Test score of 60 or below meant no chemo | The Prosigna test reads 50 genes and scores recurrence risk from 0 to 100; a low score meant hormone therapy alone. |
| Benefit held even with cancer in the lymph nodes | Many participants had node-positive disease, the group where skipping chemo had been least certain. |
| Median follow-up only 4 years | These are early results; hormone-driven breast cancer can return much later, so longer tracking still matters. |
What OPTIMA tested, and in whom
The trial enrolled people aged 40 and over with estrogen receptor-positive, HER2-negative early breast cancer, the most common type. Critically, everyone in it was high clinical risk: either the cancer had spread to as many as nine lymph nodes, or the tumour was at least 3 centimetres across. These are exactly the patients an oncologist would normally steer toward chemotherapy on the spot.
Instead, participants were randomly split. One group got the standard path, chemotherapy followed by hormone-blocking therapy. The other group had their tumour sent for a Prosigna test, made by Veracyte, which reads the activity of 50 genes and returns a “risk of recurrence” score. A score above 60 meant chemotherapy was added, as usual. A score of 60 or below meant the patient was steered to hormone therapy alone and skipped chemo entirely.
The point was to see whether trusting the biology of the tumour, rather than its size and spread, was safe.
The number that matters
It was. The main measure was how many people stayed free of invasive breast cancer at five years. In the standard-chemotherapy group, that was 91.8%. In the test-guided group, where two thirds skipped chemo, it was 90.3%. The difference is 1.5 percentage points, and the trial was designed as a non-inferiority study, meaning it set out to prove the test-guided approach was not meaningfully worse. It cleared that bar (hazard ratio 1.03, non-inferiority p = 0.006).
The pattern held where it mattered most. Among patients the test scored as low risk, five-year survival free of invasive cancer was 94.8% with standard chemo and 93.6% when guided by the test. The results carried across subgroups that doctors worry about, including premenopausal women and people with cancer in several lymph nodes. Distant recurrence, the cancer coming back elsewhere in the body, was also close between the groups, 94.1% versus 93.3% free at five years.
Why this is a bigger deal than the usual “may help” headline
Gene tests that guide chemotherapy decisions are not new. The Oncotype DX test has been used for years, mostly in lower-risk, node-negative disease. What OPTIMA adds is evidence in a harder group: higher clinical risk, and many patients with cancer already in their lymph nodes. That is precisely where oncologists have been most reluctant to hold back chemo, because the stakes of being wrong feel higher.
Non-inferiority is doing quiet but important work here. This trial does not claim skipping chemo is better. It claims that, for the two thirds of these patients with low-risk tumour biology, adding chemotherapy did not buy them meaningfully more protection. If chemo is not adding protection, then everything it costs, the months of side effects, the long-term heart and nerve risks, the time off work and life, is cost without benefit. Removing it is the win.
The researchers estimate more than 5,000 patients a year in the NHS alone could avoid chemotherapy on the strength of these findings.
What this study cannot tell you yet
- Five years is early for this cancer. Estrogen receptor-positive breast cancer is known for coming back late, sometimes ten or fifteen years after diagnosis. The median follow-up here is four years. The result is strong so far, but the long tail is the real test, and it is not in yet.
- It is a “not worse” result, not a “better” one. OPTIMA shows the test-guided path is not meaningfully worse than chemo for low-risk tumours. It does not show anyone lived longer by skipping chemo, only that they were spared it without a measurable penalty.
- The test maker helped fund it. The trial was largely publicly funded, with 5.7 million pounds from the UK’s National Institute for Health and Care Research, but Veracyte, which makes the Prosigna test, contributed 1.8 million pounds. That is disclosed and normal for device trials, and worth knowing.
- Access is not automatic. A positive trial is not the same as a funded, routine test at your hospital. Whether you can get gene-expression testing depends on where you are treated.
What to do if this affects you or someone you love
If you or a family member has just been diagnosed with hormone-driven, HER2-negative early breast cancer and chemotherapy has been raised, this is a reason to ask one specific question rather than to assume anything. Ask the treating oncologist whether a gene-expression test, such as Prosigna, is available and appropriate for your case, and what your tumour’s recurrence score would mean for the chemo decision. For some people, particularly with high-risk tumour biology, chemotherapy will still be the right call. The value of OPTIMA is that “do I actually need this chemo?” is now a fair, evidence-backed question to put to your team, not a hope.
As Professor Iain MacPherson of the University of Glasgow, co-chief investigator, put it, the trial offers “practice-changing evidence that we can safely reduce the use of chemotherapy for many patients with hormone-sensitive breast cancer.”
Related Coverage
Sources:
- UCL News, “Gene test can safely spare many breast cancer patients chemotherapy” (https://www.ucl.ac.uk/news/2026/may/gene-test-can-safely-spare-many-breast-cancer-patients-chemotherapy)
- The ASCO Post, “Phase III OPTIMA Trial: Many Patients With ER-Positive, HER2-Negative Breast Cancer May Be Able to Avoid Chemotherapy” (https://ascopost.com/issues/august-25-2026/phase-iii-optima-trial-many-patients-with-er-positive-her2-negative-breast-cancer-may-be-able-to-avoid-chemotherapy/)
- Journal of Clinical Oncology, “First results from the OPTIMA phase III randomized non-inferiority trial of test-directed chemotherapy in high clinical risk ER-positive HER2-negative early breast cancer” (https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.500)
Disclaimer: This article is for general information only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider about any medical condition or before making changes to your care.